Regeneron Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Regeneron Pharmaceuticals has a total shareholder equity of $28.2B and total debt of $2.0B, which brings its debt-to-equity ratio to 7%. Its total assets and total liabilities are $36.1B and $7.9B respectively. Regeneron Pharmaceuticals's EBIT is $4.1B making its interest coverage ratio -7.3. It has cash and short-term investments of $9.8B.
Key information
7.0%
Debt to equity ratio
US$1.98b
Debt
| Interest coverage ratio | -7.3x |
| Cash | US$9.81b |
| Equity | US$28.21b |
| Total liabilities | US$7.88b |
| Total assets | US$36.09b |
Recent financial health updates
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Recent updates
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Financial Position Analysis
Short Term Liabilities: REGN's short term assets ($19.1B) exceed its short term liabilities ($3.5B).
Long Term Liabilities: REGN's short term assets ($19.1B) exceed its long term liabilities ($4.4B).
Debt to Equity History and Analysis
Debt Level: REGN has more cash than its total debt.
Reducing Debt: REGN's debt to equity ratio has increased from 0% to 7% over the past 5 years.
Debt Coverage: REGN's debt is well covered by operating cash flow (205.2%).
Interest Coverage: REGN earns more interest than it pays, so coverage of interest payments is not a concern.